Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Efficacy of Polynucleotide for the Recovery of Depressed Lesions Following Steroid-Based Lipolysis Injections

Park SM., Oh SM., Oh M., Lee DK.

Retrospective Study on Face & Skin, published in Clin Cosmet Investig Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Clin Cosmet Investig Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42266763
PMCID
PMC13242990
DOI
10.2147/ccid.s603237

Abstract (original English)

Background Steroid-containing lipolysis injections may rarely induce facial lipoatrophy, resulting in persistent contour deformities and psychological distress. In compromised tissues, conventional fillers may pose safety concerns, prompting interest in treatment approaches that support local tissue recovery. Objective To evaluate the clinical efficacy and safety of polynucleotide (PN) injection for facial lipoatrophy caused by steroid-containing lipolysis injections. Methods This retrospective clinical study included six patients who developed facial lipoatrophy following steroid-containing lipolysis injectionsand were treated with PN (Rejuran ® , 20 mg/mL). PN was administered using a combination of intradermal microinjections and superficial subcutaneous bolus injections at 2-4-week intervals. Clinical outcomes were assessed using the Physician's Global Assessment (PGA; 1-5 scale) based on standardized photographic comparisons, along with patient-reported satisfaction. Results All patients demonstrated meaningful improvement in facial contour following PN treatment. Three patients achieved near-complete resolution (PGA 5), while the remaining three showed substantial improvement (PGA 4). Improvement progressed gradually with repeated sessions. No treatment-related adverse events were observed. Conclusion PN injection appears to be a safe and effective tissue-supportive optio

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research